Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24824548 | 1.00 | KDM1A (0.42) | KDM1ASCDPDE4DEGFRDYRK1A | |
| SCHEMBL23579154 | 0.86 | KDM1A (0.41) | KDM1APDE4DEGFROGAHRH4 | |
| SCHEMBL15740731 | 0.86 | EGFR (0.50) | KDM1APDE4DEGFRDYRK1AOGA | |
| SCHEMBL15740505 | 0.86 | EGFR (0.50) | KDM1APDE4DEGFRDYRK1AOGA | |
| SCHEMBL23578666 | 0.86 | KDM1A (0.41) | KDM1APDE4DEGFROGAHRH4 | |
| SCHEMBL23579429 | 0.86 | KDM1A (0.41) | KDM1APDE4DEGFROGAHRH4 | |
| SCHEMBL23578720 | 0.86 | KDM1A (0.41) | KDM1APDE4DEGFROGAHRH4 | |
| SCHEMBL23578665 | 0.86 | KDM1A (0.41) | KDM1APDE4DEGFROGAHRH4 | |
| SCHEMBL22464585 | 0.86 | EGFR (0.50) | KDM1APDE4DEGFRDYRK1AOGA | |
| SCHEMBL16374375 | 0.86 | EGFR (0.50) | KDM1APDE4DEGFRDYRK1AOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885SCD 4666/4885PDE4D 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.